1.Overview of Acute Promyelocytic Leukemia.
Korean Journal of Pediatric Hematology-Oncology 1999;6(2):213-221
No available abstract.
Leukemia, Promyelocytic, Acute*
2.A case of microgranular acute promyelocytic leukemia with positive reaction of nonspecific esterase.
Yiel Hea SEO ; Wha Soon CHUNG ; Think You KIM
Korean Journal of Hematology 1991;26(2):435-439
No abstract available.
Carboxylesterase*
;
Leukemia, Promyelocytic, Acute*
3.A case of microgranular acute promyelocytic leukemia.
Hyun Young CHI ; Hee Sun JEON ; Young Joo CHA ; Sang Jae LEE
Korean Journal of Hematology 1991;26(1):195-200
No abstract available.
Leukemia, Promyelocytic, Acute*
4.Immature Teratoma and Subsequent Acute Promyelocytic Leukemia in a Pediatric Patient With XYY Syndrome.
Ju Heon PARK ; Hyun Woo CHOI ; Bo Young SEO ; Min Goo KANG ; Soo Hyun KIM ; Hee Jo BAEK ; Hoon KOOK ; Myung Geun SHIN
Annals of Laboratory Medicine 2015;35(5):544-547
No abstract available.
Humans
;
Leukemia, Promyelocytic, Acute*
;
Teratoma*
5.Molecular methods for genomic analyses of variant PML-RARA or other RARA-related chromosomal translocations in acute promyelocytic leukemia.
Min Jin KIM ; John Jeongseok YANG ; Claus MEYER ; Rolf MARSCHALEK ; Tae Sung PARK
Korean Journal of Hematology 2012;47(4):307-308
No abstract available.
Leukemia, Promyelocytic, Acute
;
Translocation, Genetic
6.The Bromodomain Inhibitor JQ1 Enhances the Responses to All-trans Retinoic Acid in HL-60 and MV4-11 Leukemia Cells
Changhee KANG ; C Yoon KIM ; Hyuk Soon KIM ; Se Pill PARK ; Hyung Min CHUNG
International Journal of Stem Cells 2018;11(1):131-140
All-trans retinoic acid (ATRA) is a highly effective treatment for acute promyelocytic leukemia (APL), a cytogenetically distinct subtype of acute myeloid leukemia (AML). However, ATRA-based treatment is not effective in other subtypes of AML. In non-APL AML, ATRA signaling pathway is impaired or downmodulated, and consequently fails to respond to pharmacological doses of ATRA. Therefore, complementary treatment strategies are needed to improve ATRA responsiveness in non-APL AML. In this study, we investigated the combined effect of ATRA and bromodomain inhibitor JQ1, proven to have potent anti-cancer activity mainly through inhibition of c-Myc. We showed that the combination of ATRA with JQ1 synergistically inhibited proliferation of AML cells. The synergistic growth inhibition was resulted from differentiation or apoptosis depending on the kind of AML cells. Concomitantly, the combined treatment of ATRA and JQ1 caused greater depletion of c-Myc and hTERT expression than each agent alone in AML cells. Taken together, these findings support the rationale for the use of the combination of ATRA and JQ1 as a therapeutic strategy for the treatment of AML.
Apoptosis
;
Leukemia
;
Leukemia, Myeloid, Acute
;
Leukemia, Promyelocytic, Acute
;
Tretinoin
8.ATRA- an unique drug with effective treatment of the acute promyelocytic leukemia.
Journal of Vietnamese Medicine 2001;263(9):92-14
46 patients with acute promyelocytic leukemia (APL) have been treated by ATRA (all trans retinoic acid). The result showed that 33 patients (72%) were complete remission. Two patients in relapse have been treated by ATRA plus As2O3 (arsenic trioside). The both patients were complete remission. The results of the present study showed that ATRA is standard drug of remission of induction in APL.
Leukemia, Promyelocytic, Acute
;
therapy
;
drug therapy
;
therapeutics
9.Acute promyelocytic leukemia with normal karyotype initially diagnosed on bone marrow touch imprints.
Blood Research 2015;50(3):130-130
No abstract available.
Bone Marrow*
;
Karyotype*
;
Leukemia, Promyelocytic, Acute*
Result Analysis
Print
Save
E-mail